EchoIQ Limited (ASX:EIQ) delivered a stunning 27.02% gain on 25 June 2026, with shares surging to AUD 1.58 on the back of one of the most consequential announcements in the company's history — a binding heads of agreement with global health imaging powerhouse Pro Medicus (ASX: PME) for a strategic investment of up to AUD 20 million and a US commercial reseller partnership. The deal has catapulted EchoIQ's market capitalisation to AUD 1.04 billion, an extraordinary milestone for a company that was trading at just AUD 0.165 at its 12-month low — representing a gain of over 600% for investors who entered at those levels.
The volume of newsflow, institutional validation, and commercial momentum converging on EIQ today marks a clear inflection point for the stock.
What Just Happened? The Recent Update
The headline announcement is the binding heads of agreement with Pro Medicus, under which Pro Medicus has committed to an initial AUD 10 million investment in EchoIQ through secured convertible notes. Pro Medicus also holds the right to invest a further AUD 10 million upon EchoIQ's EchoSolv HF product receiving US FDA clearance — meaning the total commitment could reach AUD 20 million. Crucially, Pro Medicus has also agreed to become a reseller of the EchoSolv platform, giving EchoIQ access to Pro Medicus' extensive global network of leading US health systems, academic medical centres, and enterprise healthcare customers built over decades.
The FDA submission for EchoSolv HF — EchoIQ's AI-powered heart failure detection software — remains on track, with an outcome expected in the near term. A positive FDA decision would trigger the second AUD 10 million tranche of investment automatically.
The day prior, on 24 June 2026, EchoIQ also announced two significant appointments: Matthew Dodds as Chief Financial Officer and Dr. Vinod Thourani — an internationally recognised authority in structural heart disease and cardiovascular surgery — as Clinical Advisor. These appointments reinforce the company's US expansion strategy and lend additional clinical credibility ahead of the FDA regulatory process.
Key Reasons Behind the Uptick
Today's 27% gain is driven almost entirely by the Pro Medicus deal — a transaction that does several things at once. It provides EchoIQ with a substantial capital injection to accelerate US commercialisation, delivers a tier-one reseller with an established hospital network, and serves as arguably the most powerful third-party validation the company has ever received. Pro Medicus is one of the most respected healthcare imaging companies in the world, and its decision to back EchoIQ sends a clear signal to the broader market about the quality of the EchoSolv technology and its commercial potential.
EchoIQ already holds FDA clearance for its Aortic Stenosis detection product, which is actively being deployed across US health systems including Mount Sinai in New York. The company also has an active research collaboration with the Mayo Clinic — the number-one ranked hospital system in the US — to evaluate its AI platform for cardiac risk stratification in oncology patients, opening up the emerging cardio-oncology market.
Key Growth Catalysts
The near-term FDA decision on EchoSolv HF represents the single largest catalyst on the horizon. Heart failure is a substantially larger addressable market than aortic stenosis, and an existing CMS reimbursement code established in April 2026 for AI cardiac imaging analysis means EchoIQ may be able to generate revenues from US payers without the lengthy wait for a Category I code. The Pro Medicus reseller arrangement supercharges the distribution potential of that approval the moment it arrives.
Beyond FDA, the Mayo Clinic collaboration, the Mount Sinai deployment, and the company's strengthened leadership team all point to an organisation that is building the commercial infrastructure needed to scale across the world's largest healthcare market.
Risks to Watch
Despite today's extraordinary momentum, risks remain real. The FDA decision on EchoSolv HF is not guaranteed — regulatory outcomes are inherently uncertain, and any delay or rejection would likely trigger a significant reversal in the share price. The convertible note structure carries its own terms: notes that are not converted must be redeemed within 24 months at an interest rate of 12.5% per annum, with redemption at the lower of AUD 1.05 or the five-day VWAP — introducing potential dilution risk.
EIQ is not covered by any major institutional broker, meaning research and investor education remain limited. No dividend is paid. At a market cap of AUD 1.04 billion, the stock is now pricing in considerable future success, leaving little room for execution missteps.



_11_16_2026_14_22_42_725575.jpg)


Please wait processing your request...